The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: A cost-effectiveness analysis

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1217-1222

  Heinzel, Alexander ^a,b   Müller, Dirk ^c   Langen, Karl Josef ^b   Blaum, Marcus ^d   Verburg, Frederik Anton ^a   Mottaghy, Felix M ^a   Galldiks, Norbert ^b,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

18F FET PET; Cost effectiveness analysis; Decision tree model; Recurrent glioma

Indexed keywords

BEVACIZUMAB; IRINOTECAN; O (2 FLUOROETHYL)LEVO TYROSINE F18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; CAMPTOTHECIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; TYROSINE;

ARTICLE; BRAIN SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DIAGNOSTIC VALUE; DRUG MONITORING; FOLLOW UP; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REIMBURSEMENT; 18F-FET PET; BRAIN TUMOR; COST BENEFIT ANALYSIS; COST-EFFECTIVENESS ANALYSIS; DECISION TREE MODEL; DISEASE FREE SURVIVAL; ECONOMICS; GLIOMA; MONTE CARLO METHOD; PATHOLOGY; RECURRENT DISEASE; RECURRENT GLIOMA; SCINTISCANNING; TREATMENT OUTCOME;

18F-FET PET; COST-EFFECTIVENESS ANALYSIS; DECISION TREE MODEL; RECURRENT GLIOMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CAMPTOTHECIN; COST-BENEFIT ANALYSIS; DECISION TREES; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MONTE CARLO METHOD; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TREATMENT OUTCOME; TYROSINE;

EID: 84881431773     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.120089     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17:2572-2578.
3. Xu T, Chen J, Lu Y, Wolff JE. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer. 2010;10:252.
4. Friedman HS, Prados MD,Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
5. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.
6. Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio [abstract]. Neuro-Oncol. 2012;14:vi101-vi105.
7. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48: 1468-1481.
8. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
9. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8: 1277-1280.
10. Wick W, Wick A, Weiler M,Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr Neurol Neurosci Rep. 2011;11:305-312.
11. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
12. Pope WB, Young JR, Ellingson BM. Advances in MR imaging assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep. 2011; 11:336-344.
13. 18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287-294.
14. 18F]fluoroethyl) -L-tyrosine PET combined with MR imaging improves the diagnostic assessment of cerebral gliomas. Brain. Mar 2005;128:678-687.
15. 18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505-511.
16. 18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol. 2008;88:27-35.
17. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. Mar 2006;47:393-403.
18. 18F-fluoroethyl)-L-tyrosine PET in comparison to MR imaging. J Nucl Med. Jul 2012;53:1048-1057.
19. 18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32: 1018-1025.
20. 18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792-800.
21. 18F]fluoroethyl- L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging. 2013;40:22-33.
22. 18F- fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent highgrade glioma. J Nucl Med. 2011;52:856-864.
23. Heinzel A, Stock S, Langen KJ, Muller D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging. 2012;39:1089-1096.
24. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics. 1996;9:113-120.
25. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making. Summer 1985;5:157-177.
26. Burgos JL, Gaebler JA, Strathdee SA, Lozada R, Staines H, Patterson TL. Costeffectiveness of an intervention to reduce HIV/STI incidence and promote condom use among female sex workers in the Mexico-US border region. PLoS ONE. 2010;5:e11413.
27. Heinzel A, Stock S, Langen KJ, Muller D. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas. J Nucl Med. 2012;53:552-558.
28. Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis. 1999;5:321-328.
29. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1-18.
30. Langen KJ, Floeth FW, Stoffels G, Hamacher K, Coenen HH, Pauleit D. Improved diagnostics of cerebral gliomas using FET PET [in German]. Z Med Phys. 2007;17:237-241